Active tumor-targeted delivery of PEG-protein via transferrin–transferrin-receptor system

References

• Ali SA, Joao HC, Hammerschmid F, Eder J, Steinkasserer A. Transferrin Trojan horses as a rational approach for the biological delivery of therapeutic peptide domains. J Biol Chem 1999; 274: 24073
   Google Scholar
• Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750–763
   PubMed Web of Science ®Google Scholar
• Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998; 1: 352–356
   Google Scholar
• Barker TH, Klinger MM, Feldman DS, Fuller GM, Hagood JS. Spectrophotometric analysis for determining the average number of poly(ethylene) glycol molecules on PEGylated proteins utilizing a protein digestion step. Anal Biochem 2001; 290: 382–385
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantification of protein utilizing the principles of protein–dye binding. Anal Biochem 1976; 72: 248–254
   PubMed Web of Science ®Google Scholar
• Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261–1277
   PubMed Web of Science ®Google Scholar
• Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 1999; 17: 780–783
   PubMed Web of Science ®Google Scholar
• Citores L, Ferreras JM, Muñoz R, Benítez J, Jiménez P, Girbés T. Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l. Cancer Lett 2002; 184: 29–35
   PubMed Web of Science ®Google Scholar
• Dash PR, Read ML, Fisher KD, Howard KA, Wolfert M, Oupicky D, Subr V, Strohalm J, Ulbrich K, Seymour LW. Decreased binding to proteins and cells of polymeric gene delivery vectors surface modified with a multivalent hydrophilic polymer and retargeting through attachment of transferrin. J Biol Chem 2000; 275: 3793–3802
   PubMed Web of Science ®Google Scholar
• Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 2003; 55: 1279–1291
   PubMed Web of Science ®Google Scholar
• Fritzer M, Szekeres T, Szüts V, Jarayam HN, Golddenberg H. Cytotoxic effects of a doxorubicin–transferrin conjugate in multidrug-resistant KB cells. Biochem Pharmacol 1996; 51: 489–493
   PubMed Web of Science ®Google Scholar
• Han H, Amidon G. Targeted prodrug design to optimize drug delivery. AAPS PharmSci 2000; 2: 1–11
   Google Scholar
• Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY. Tumor cell targeting of transferrin–PEG–TNF-α conjugate via a receptor-mediated delivery system: Design, synthesis and biological evaluation. Bioconjug Chem 2007; 18: 41–49
   PubMed Web of Science ®Google Scholar
• Kratz F, Beyer U, Schumacher P, Krüger M, Zahn H, Roth T, Fiebig HH, Unger C. Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates. Bioorg Med Chem Lett 1997; 7: 617–622
   Web of Science ®Google Scholar
• Kursa M, Walker GF, Roessler V, Ogris M, Roedl W, Kircheis R, Wagner E. Novel shielded transferrin–polyethylene glycol–polyethylenimine/DNA complexes for systemic tumor-targeted gene transfer. Bioconjug Chem 2003; 14: 222–231
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structure proteins during the assembly of the head of bacteriaphage T4. Nature (London) 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Li YP, Pei YY, Ding J, Shen ZM, Zhang XY, Gu ZH, Zhou JJ. PEGylated recombinant human tumor necrosis factor alpha: Preparation and anti-tumor potency. Acta Pharmacol Sin 2001a; 22: 549–555
   PubMed Web of Science ®Google Scholar
• Li YP, Pei YY, Zhou ZH, Zhang XY, Gu ZH, Ding J, Gao XJ, Zhu JH. Pegylated recombinant human tumor necrosis factor alpha: Pharmacokinetics and anti-tumor effects. Biol Pharm Bull 2001b; 24: 666–670
   PubMed Web of Science ®Google Scholar
• Li H, Sun H, Qian ZM. The role of the transferrin–transferrin-receptor system in drug delivery and targeting. Trends Pharmacol Sci 2002; 23: 206–209
   PubMed Web of Science ®Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189–207
   PubMedGoogle Scholar
• Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319–328
   PubMed Web of Science ®Google Scholar
• Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kobayashi H, Eriguchi M, Yanagie H. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin–PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release 2004; 98: 195–207
   PubMed Web of Science ®Google Scholar
• McGoff P, Baziotis AC, Maskiewicz R. Analysis of polyethylene glycol modified superoxide dismutase by chromatographic, electrophoresis, light scattering, chemical and enzymatic methods. Chem Pharm Bull 1988; 36: 3079–3091
   PubMed Web of Science ®Google Scholar
• Riddles PW, Blakeley RL, Zerner B. Ellman's reagent: 5,5-dithiobis(2-nitrobenzoic acid)–a reexamination. Anal Biochem 1979; 94: 75–81
   PubMed Web of Science ®Google Scholar
• Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese FM. PEG–Ara-C conjugates for controlled release. Eur J Med Chem 2004; 39: 123–133
   PubMed Web of Science ®Google Scholar
• Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2000; 277: 39–61
   Google Scholar
• Yoshioka Y, Tsutsumi Y, Ikemizu S, Yamamoto Y, Shibata H, Nishibata T, Mukai Y, Okamoto T, Taniai M, Kawamura M, Abe Y, Nakagawa S, Nagata S, Yamagata Y, Mayumi T. Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency. Biochem Biophys Res Commun 2004; 315: 808–814
   PubMed Web of Science ®Google Scholar